Oxaprozin

• Description:

  Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].

• Product Name Alternative:

  Oxaprozinum; Wy21743

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Akt; Apoptosis; COX; IKK; NF-κB

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Immunology/Inflammation; NF-κB; PI3K/Akt/mTOR

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Oxaprozin.html

• Purity:

  99.94

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C (O) CCC1=NC (C2=CC=CC=C2) =C (C3=CC=CC=C3) O1

• Molecular Formula:

  C18H15NO3

• Molecular Weight:

  293.32

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Ottonello L, et al. Delayed apoptosis of human monocytes exposed to immune complexes is reversed byoxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157 (2) :294-306.|[2]Montecucco F, et al. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol. 2009;2009:478785.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  COX-1; COX-2; IKK; NF-κB

• CAS Number:

  21256-18-8